RESUMEN
The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures. Neonates were found to have lower clearance, higher volume of distribution, and a longer half-life as compared with older children and adults. Mild somnolence was the only adverse effect.
Asunto(s)
Anticonvulsivantes/farmacocinética , Piracetam/análogos & derivados , Convulsiones/tratamiento farmacológico , Anticonvulsivantes/uso terapéutico , Peso Corporal , Cromatografía Liquida , Creatinina/sangre , Femenino , Semivida , Humanos , Recién Nacido , Unidades de Cuidado Intensivo Neonatal , Levetiracetam , Masculino , Análisis Multivariante , Piracetam/farmacocinética , Piracetam/uso terapéutico , Estudios Prospectivos , Espectrometría de Masas en TándemRESUMEN
To assess whether levetiracetam elimination is influenced by enzyme inducing antiepileptic drugs (EIAEDs), serum levetiracetam levels were determined at frequent intervals after a single oral 1000mg dose in 15 subjects co-medicated with EIAEDs and 15 matched controls. The EIAED group showed a higher levetiracetam oral clearance (p=0.01) and a shorter half-life (p=0.02) than controls. Although the magnitude of interaction is relatively modest, it could have clinical significance for some patients.